Literature DB >> 22435072

Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany.

Anke Stroet, Claudia Hemmelmann, Michaela Starck, Uwe Zettl, Jan Dörr, Paul Friedemann, Friedmann Paul, Peter Flachenecker, Vinzenz Fleischer, Frauke Zipp, Holger Nückel, Bernd C Kieseier, Andreas Ziegler, Ralf Gold, Andrew Chan.   

Abstract

BACKGROUND: The incidence of therapy-related acute leukaemia (TRAL) in mitoxantrone treatment in multiple sclerosis (MS) is controversially discussed. METHODS AND
RESULTS: In a retrospective meta-analysis from six centres, we observed six cases of acute myeloid leukaemia (AML) (incidence 0.41% for patients with mean follow up after end of treatment of 3.6 years, n = 1.156; incidence 0.25% for all patients, n = 2.261). Potential influencing factors such as myelotoxic or glucocorticosteroid pretreatment/cotreatment were present in all but one case of TRAL. Between 1990 and 2010, 11 cases of TRAL were reported to the Drug Commission of the German Medical Association (estimated risk of 0.09-0.13%).
CONCLUSIONS: Regional differences in reported TRAL incidence may point to confounding cofactors such as administration protocols and cotreatments.

Entities:  

Keywords:  escalation therapy; leukaemia; mitoxantrone; multiple sclerosis; risk profile

Year:  2012        PMID: 22435072      PMCID: PMC3302202          DOI: 10.1177/1756285611433318

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN: 1756-2856            Impact factor:   6.570


  8 in total

Review 1.  Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  James J Marriott; Janis M Miyasaki; Gary Gronseth; Paul W O'Connor
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

2.  Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.

Authors:  E Le Page; E Leray; G Edan
Journal:  Mult Scler       Date:  2011-02-15       Impact factor: 6.312

3.  ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.

Authors:  S Cotte; N von Ahsen; N Kruse; B Huber; A Winkelmann; U K Zettl; M Starck; N König; N Tellez; J Dörr; F Paul; F Zipp; F Lühder; H Koepsell; H Pannek; X Montalban; R Gold; A Chan
Journal:  Brain       Date:  2009-07-15       Impact factor: 13.501

4.  Multiple sclerosis registry in Germany: results of the extension phase 2005/2006.

Authors:  Peter Flachenecker; Kristin Stuke; Wolfgang Elias; Matthias Freidel; Judith Haas; Dorothea Pitschnau-Michel; Sebastian Schimrigk; Uwe K Zettl; Peter Rieckmann
Journal:  Dtsch Arztebl Int       Date:  2008-02-15       Impact factor: 5.594

5.  Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.

Authors:  Ana M Pascual; Neus Téllez; Isabel Boscá; Javier Mallada; Antonio Belenguer; Inmaculada Abellán; Angel P Sempere; Pascual Fernández; Ma José Magraner; Francisco Coret; Miguel A Sanz; Xavier Montalbán; Bonaventura Casanova
Journal:  Mult Scler       Date:  2009-10-13       Impact factor: 6.312

Review 6.  A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis.

Authors:  R G Ghalie; E Mauch; G Edan; H P Hartung; R E Gonsette; S Eisenmann; E Le Page; M D Butine; D E De Goodkin
Journal:  Mult Scler       Date:  2002-10       Impact factor: 6.312

7.  Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?

Authors:  R Ellis; M Boggild
Journal:  Mult Scler       Date:  2009-02-27       Impact factor: 6.312

8.  Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.

Authors:  Hans-Peter Hartung; Richard Gonsette; Nikolaus König; Hubert Kwiecinski; Andreas Guseo; Sean P Morrissey; Hilmar Krapf; Thomas Zwingers
Journal:  Lancet       Date:  2002 Dec 21-28       Impact factor: 79.321

  8 in total
  16 in total

1.  [Current immunotherapy of multiple sclerosis].

Authors:  F Paul; K Ruprecht
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

Review 2.  Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.

Authors:  A Salmen; R Gold; A Chan
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

Review 3.  Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

Authors:  Joachim Havla; Clemens Warnke; Tobias Derfuss; Ludwig Kappos; Hans-Peter Hartung; Reinhard Hohlfeld
Journal:  Dtsch Arztebl Int       Date:  2016-12-26       Impact factor: 5.594

Review 4.  Neuromyelitis optica: clinical features, immunopathogenesis and treatment.

Authors:  S Jarius; B Wildemann; F Paul
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

Review 5.  Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 1.

Authors:  Aryan Rafiee Zadeh; Mozhde Askari; Niloufar Nasr Azadani; Akram Ataei; Keyvan Ghadimi; Nooshin Tavoosi; Masih Falahatian
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2019-08-15

6.  Induction therapy for patients with multiple sclerosis: why? When? How?

Authors:  Gilles Edan; Emmanuelle Le Page
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

7.  Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?

Authors:  Anja Mähler; Silvia Mandel; Mario Lorenz; Urs Ruegg; Erich E Wanker; Michael Boschmann; Friedemann Paul
Journal:  EPMA J       Date:  2013-02-18       Impact factor: 6.543

Review 8.  Ultrahigh field MRI in clinical neuroimmunology: a potential contribution to improved diagnostics and personalised disease management.

Authors:  Friedemann Paul; Jens Wuerfel; Tim Sinnecker; Joseph Kuchling; Petr Dusek; Jan Dörr; Thoralf Niendorf
Journal:  EPMA J       Date:  2015-08-27       Impact factor: 6.543

9.  The transition from first-line to second-line therapy in multiple sclerosis.

Authors:  Jan Dörr; Friedemann Paul
Journal:  Curr Treat Options Neurol       Date:  2015-06       Impact factor: 3.972

Review 10.  Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).

Authors:  Corinna Trebst; Sven Jarius; Achim Berthele; Friedemann Paul; Sven Schippling; Brigitte Wildemann; Nadja Borisow; Ingo Kleiter; Orhan Aktas; Tania Kümpfel
Journal:  J Neurol       Date:  2013-11-23       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.